NICE rejects Botox (Allergan) for Migraine prevention

NICE,the National Institute for Health and Clinical Excellence has published draft guidance rejecting the use of Botox (botulinum toxin type A)from Allergan, to prevent headaches in adult patients experiencing chronic Migraines. The Institute's committee of experts has concluded that there is not enough evidence to recommend the drug, and so has asked that its manufacturer Allergan provide additional information in support of its use on the NHS. The Scottish Medicines Consortium refused to recommend the drug for Migraine prevention last year. The clinical benefit was seen as modest and confused by the placebo effect.